Aclaris Therapeutics Inc (ACRS) is Initiated by Guggenheim to Buy, Price Target at $35

Aclaris Therapeutics Inc (ACRS) was Initiated by Guggenheim to “Buy” and the brokerage firm has set the Price Target at $35. Guggenheim advised their investors in a research report released on Jun 10, 2016.

In a different news, on Oct 13, 2015, Albert Cha (director) purchased 454,545 shares at $11.00 per share price.

Aclaris Therapeutics Inc. is a United States-based clinical-stage specialty pharmaceutical company. The Company is focused on identifying developing and commercializing differentiated therapies in dermatology. The Company’s drug candidate A-101 is being developed as an in-office treatment for seborrheic keratosis a non-cancerous skin tumor as well as for other cutaneous indications such as common warts. In addition the Company is engaged in developing a portfolio of Janus Kinase (JAK) inhibitor compounds for the treatment of alopecia areata and other dermatological conditions. The Company’s products A-201 and A-301 are indicated for the treatment of alopecia areata. The Company’s A-101 product is entering Phase III clinical trials for the treatment of seborrheic keratosis and Phase II clinical trials for the treatment of common warts. The Company’s A-201 and A-301 products are in pre- clinical stage.

Aclaris Therapeutics Inc

Leave a Reply

Aclaris Therapeutics Inc - Is it time to Sell?

Top Brokerage Firms are advising their investors on Aclaris Therapeutics Inc. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.